The present disclosure relates to a method for producing a composition, wherein the method comprises the steps of co-culturing immortalized fibroblasts and immortalized keratinocytes, thereby producing secretion; separating the secretion from the fibroblasts and keratinocytes; and providing a pharmaceutically acceptable composition comprising the secretion. The present disclosure also relates to the composition obtainable by the method, wherein the composition preferably is a pharmaceutical composition for medical use, preferably for use in the treatment of a wound, preferably a chronic or acute wound.

The present invention relates to artificial skin using fibroblasts and keratinocytes, and more particularly, to a manufacturing method of artificial skin using cells differentiated from induced pluripotent stem cells (iPSCs). To this end, there is provided a manufacturing method of artificial skin using cells differentiated from iPSCs including the steps of: preparing induced pluripotent stem cells (iPSCs) of a donor (S100); performing differentiating fibroblasts from the iPSCs (S140) and differentiating keratinocytes from the iPSCs (S120) simultaneously or sequentially; injecting the fibroblasts and the keratinocytes using a 3D printer (S160); and manufacturing artificial skin by co-culturing the injected fibroblasts and keratinocytes (S160).

The present invention relates, in various embodiments, to methods of producing a tissue-mimetic construct having a basement membrane, methods of producing an acellular scaffold containing an extracellular matrix (ECM), methods of producing a scaffold comprising a hydrogel that is enriched in ECM components, methods of treating a condition in a subject in need thereof with a tissue-mimetic construct having a basement membrane, and methods of assessing whether an agent is suitable for administering to a tissue. The invention further relates to tissue-mimetic constructs and scaffolds produced in accordance with the methods of the invention.

The present invention relates generally to compositions for wound closure. More specifically, the present invention provides human skin equivalents engineered to express exogenous polypeptides (e.g., antimicrobial polypeptides and keratinocyte growth factor 2) and compositions and methods for making human skin equivalents engineered to express exogenous polypeptides. In addition, the present invention provides methods for treatment of wounds with human skin equivalents engineered to express exogenous polypeptides.

A method for manufacturing a skin chip according to an exemplary embodiment of the present disclosure may include: a step of forming first and second PDMS layers disposed on both surfaces of a porous membrane and each having a microfluidic channel through which a culture medium is transferred to both surfaces of the porous membrane; a step of forming first and second MEA substrate layers disposed on the outer surfaces of the first and second PDMS layers, respectively, and having metal electrodes for measurement of TEER arranged at positions corresponding to the channels; and a step of forming first and second PMMA layers disposed on the outer surfaces of the first and second MEA substrate layers, respectively. In the method for manufacturing a skin chip according to in an exemplary embodiment of the present disclosure, the porous membrane may be made of a polycarbonate having pores of a predetermined size.

Embodiments of the present invention provide Dermal Micro-organs (DMOs), methods and apparatuses for harvesting the same. Some embodiments of the invention provide a DMO including a plurality of dermal components, which substantially retain the micro-architecture and three dimensional structure of the dermal tissue from which they are derived. An apparatus for harvesting the DMO may include, according to some exemplary embodiments, a support configuration to support a skin-related tissue structure from which the DMO is to be harvested, and a cutting tool able to separate the DMO from the skin-related tissue structure. Exemplary embodiments of the invention provide a genetically modified dermal micro-organ expressing at least one recombinant gene product. Some embodiments of the invention provide methods and apparatuses for implanting a genetically modified DMO.

An apparatus and method for the production of substitute skin that advantageously reduces the amount of donor dermal cells needed from non-wound areas of a patient having a wound to be auto-grafted is reduced by using all of the harvested skin cells. A 3D printer is used to construct a wound graft product from the harvested skin cells without wasting any of the harvested skin cells. In a case of an irregularly shaped wound, wastage of harvested skin associated with trimming is avoided.

An apparatus and method for the production of substitute skin that advantageously reduces the amount of donor dermal cells needed from non-wound areas of a patient having a wound to be auto-grafted is reduced by using all of the harvested skin cells. A 3D printer is used to construct a wound graft product from the harvested skin cells without wasting any of the harvested skin cells. In a case of an irregularly shaped wound, wastage of harvested skin associated with trimming is avoided.

The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the normal tissues that interact with vaccines in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interaction with the immune system.

The invention provides a micro-organ composite which comprises a core group of cells and an outer layer of cells, wherein the cells of the core group are mesenchymal cells and the cells of the outer layer are epithelial cells or wherein the cells of the core group are epithelial cells and the cells of the outer layer are mesenchymal cells, and wherein the core group of cells is at least partially encapsulated by the outer layer of cells.